Clinical Trials

Title   [967156-2] A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
Description   To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
IRB Number   16-289
Treatment   Multiple Sclerosis
Status   Active
Principal Name   Elizabeth Minto, M.D.
Contact Name   Tatiana Torres Herman

Email Newsletters

Connect With Us